Shionogi's Ensitrelvir Cuts COVID-19 Risk by 67% in Post-Exposure Trial
Event summary
- Shionogi's Phase 3 SCORPIO-PEP study showed ensitrelvir reduced symptomatic COVID-19 risk by 67% in exposed individuals.
- The trial involved 2,041 participants, with 2.9% of ensitrelvir recipients developing symptoms vs. 9.0% on placebo.
- Ensitrelvir demonstrated a 76% risk reduction in high-risk subgroups, with no reports of altered taste (dysgeusia).
- The U.S. FDA is reviewing ensitrelvir for post-exposure prophylaxis with a PDUFA action date of June 16, 2026.
- Ensitrelvir is already approved in Japan for COVID-19 treatment and prevention.
The big picture
Shionogi's ensitrelvir represents a potential shift in COVID-19 prevention, offering the first oral antiviral for post-exposure prophylaxis. This could address a critical gap in current treatment options, which primarily target active infections. The strategic significance lies in its ability to reduce both acute disease severity and long-term complications like long COVID, particularly in high-risk populations. The upcoming FDA decision will be pivotal in determining its global market potential.
What we're watching
- Regulatory Approval
- Whether the U.S. FDA will approve ensitrelvir for post-exposure prophylaxis by the June 2026 PDUFA date.
- Market Adoption
- The pace at which ensitrelvir could be integrated into post-exposure prophylaxis protocols if approved.
- Variant Efficacy
- How effective ensitrelvir remains against emerging variants like BA.3.2 (Cicada).
Related topics